DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Completed

Conditions: Geographic Atrophy

First Posted Date: 2023-06-06

Last Posted Date: 2025-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68563

Registration Number: NCT05891275

Locations: 🇺🇸
CorEvitas HQ, Waltham, Massachusetts, United States

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Phase 2

Recruiting

Conditions: Small Cell Lung Carcinoma
Neuroendocrine Neoplasms
Extra-pulmonary Neuroendocrine Carcinoma

Interventions: Drug: BI 764532, dose 1
Drug: BI 764532, dose 2

First Posted Date: 2023-05-31

Last Posted Date: 2025-04-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 174

Registration Number: NCT05882058

Locations: 🇩🇪
Evangelische Lungenklinik Berlin, Berlin, Germany
🇺🇸
Mayo Clinic-Arizona, Phoenix, Arizona, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 57 locations

Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

First Posted Date: 2023-05-31

Last Posted Date: 2024-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 547150

Registration Number: NCT05882071

Locations: 🇫🇷
Boehringer Ingelheim, Paris, France

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Neoplasms
Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: Obrixtamig
Drug: Ezabenlimab

First Posted Date: 2023-05-30

Last Posted Date: 2025-04-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT05879978

Locations: 🇫🇷
INS Claudius Regaud IUCT-Oncopole, Toulouse, France
🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇫🇷
CTR François Baclesse, Caen, France

and more 5 locations

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631 (C-14) formulation 1
Drug: BI 1810631
Drug: BI 1810631 (C-14) formulation 2

First Posted Date: 2023-05-30

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT05879991

Locations: 🇳🇱
ICON, Groningen, Netherlands

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

Completed

Conditions: Lung Diseases, Interstitial

First Posted Date: 2023-05-25

Last Posted Date: 2023-05-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200000

Registration Number: NCT05875532

Locations: 🇺🇸
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib

First Posted Date: 2023-05-23

Last Posted Date: 2024-09-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1798

Registration Number: NCT05870956

Locations: 🇺🇸
Medicus Economics, LCC, Milton, Massachusetts, United States

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Phase 2

Completed

Conditions: Cystic Fibrosis
Bronchiectasis

Interventions: Drug: BI 1291583
Drug: Placebo

First Posted Date: 2023-05-19

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT05865886

Locations: 🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Northwell Health Physician Partners, New York, New York, United States

and more 9 locations

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764198 (C-14) (approach 2)
Drug: BI 764198 (C-14) (approach 1)

First Posted Date: 2023-05-17

Last Posted Date: 2023-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT05863130

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1815368
Drug: Matching placebo

First Posted Date: 2023-05-15

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 59

Registration Number: NCT05857878

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy